Viral Vector Production via MHC-I Knockout
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Viral vectors used in gene therapy are recognized by the immune system due to surface-exposed major histocompatibility complex class I (MHC-I) molecules, leading to reduced efficacy and safety concerns, as they can trigger immune responses and be neutralized by pre-existing antibodies.
Innovation Solution
Genetically engineered cells are developed to decrease the expression of MHC-I on their surface, allowing for the production of enveloped viral particles with reduced surface-exposed MHC-I, thereby minimizing immune recognition and increasing the safety and efficacy of gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene therapy delivery, then genetic material can be delivered to target cells, but the viral particles are recognized and neutralized by the immune system due to surface-exposed MHC-I molecules
Solution Approach 1:
The patent removes MHC-I molecules from the surface of producer cells through genetic engineering (knocking out beta-2-microglobulin or MHC-I alpha chain genes). This extraction of the harmful component (MHC-I) from the viral particle surface eliminates the target for immune recognition while preserving the viral vector's ability to deliver genetic material to target cells.
Solution Approach 2:
The patent changes the surface composition parameter of the viral particles by reducing MHC-I expression levels on producer cells. This parameter change (from high MHC-I expression to low or no MHC-I expression) modifies the immunogenicity of the viral particles without affecting their core delivery function, thereby resolving the contradiction between delivery efficacy and immune recognition.
2Productivity
If MHC-I molecules are present on producer cell surfaces, then cells can be used for viral particle production, but MHC-I molecules are incorporated into the viral envelope and trigger immune responses
Solution Approach 1:
The patent extracts removes MHC-I molecules from the producer cell surface through genetic modification before viral particle production. This ensures that the viral envelopes are formed without incorporating MHC-I molecules, thereby eliminating the source of immune-mediated harm while maintaining productive viral particle generation.
Solution Approach 2:
The patent performs preliminary genetic engineering of producer cells to knock out MHC-I expression before initiating viral particle production. This preliminary action prevents the incorporation of MHC-I into viral envelopes from the outset, avoiding subsequent immune responses while allowing efficient viral production to proceed.
3Reliability
If viral envelope proteins are displayed on transduced cells, then viral integration occurs, but the cells become targets for immune system attack
Solution Approach 1:
The patent removes MHC-I molecules from the viral envelope through genetic modification of producer cells. This extraction prevents the display of MHC-I on transduced cells, thereby eliminating the primary target for immune recognition while preserving the viral vector's ability to integrate into and transduce target cells effectively.
Data Source
AI summary
An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.